Palvella Therapeutics Q3 2026 Results: Net Loss of $24.6M, Loss Widens
Palvella Therapeutics, Inc. (formerly Pieris Pharmaceuticals) filed its Q3 2026 10-Q following its 2024 merger with Legacy Palvella. The company is focused on developing its lead product candidate, QTORIN rapamycin, for rare skin diseases and reported 14,618,457 shares of common stock outstanding as of November 2, 2026.
- Key figure
- Net loss $24.6M